x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DPP-001281
| Product Overview | |
|---|---|
| Species | Human |
| Format | Lyophilized |
| Purity | ≥97% by SDS-PAGE |
| Nature | Synthetic |
| Target Information | |
|---|---|
| Gene Name | GHRL |
| UniProt No. | Q9UBU3 |
| Gene ID | 51738 |
| Molecular Weight | 3.374 kDa |
| Alternative Names | Appetite-regulating hormone, Growth hormone secretagogue, Growth hormone-releasing peptide, Motilin-related peptide, Protein M46Human Ghrelin (Ser3 modified), Ghrelin, h-Ghrelin, rh-Ghrelin, recombinant human Ghrelin, Ghrelin (Ser3 modified), recombinant |
| Function | Ghrelin has been identified as the endogenous ligand for the GHS-R (growth hormone secretagogues receptor). Ghrelin is expressed in the stomach, small and large intestines, and brain regions that are involved in the regulation of food intake. Both ghrelin and GHS-R expression is also detected in the heart, suggesting that Ghrelin might have some cardiovascular effects. Ghrelin administration stimulates GH secretion but also causes weight gain by increase food intake. Mature human and rat Ghrelin (28 a.a.) are produced from a 117 amino acid precursor. Ghrelin has an unusual modification at Ser3 residue that is n-octanoylated and is essential for biological activity. Ghrelin is the first known example of a bioactive peptide modified by an acyl acid |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped on dry ice. |
| Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
